Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

25 Mar 2020

Abstract excerpt

BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. METHODS: In this randomized, double-blind, phase 3 trial, we assigned,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Blood transfusion and management
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32212518
DOI: 10.1056/nejmoa1910182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaPMID 32212518Read ↗

Novel Therapeutic Advances in β-ThalassemiaSemantic proximity Read ↗

Defining curative endpoints for transfusion‐dependent β‐thalassemia in the era of gene therapy and gene editingSemantic proximity Read ↗

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?Semantic proximity Read ↗

New therapeutic targets in transfusion-dependent and -independent thalassemia.Semantic proximity Read ↗

Anemia-Relieving Pharmacotherapies for Thalassemia: A Cross-Sectional Study of Clinical Trials from Clinicaltrials.govSemantic proximity Read ↗

Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availabilitySemantic proximity Read ↗

Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.Semantic proximity Read ↗

Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.Semantic proximity Read ↗

2017 Clinical trials update in new treatments of β‐thalassemiaSemantic proximity Read ↗

Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive CrisesSemantic proximity Read ↗

Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.Semantic proximity Read ↗

Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.